The ALS Therapy Alliance (ATA) was established in 2000 to galvanize a consortium of scientists at multiple institutions to cure ALS, also known as Lou Gehrig's disease. ATA's unique, collaborative enterprise spans a variety of laboratories and universities on a global scale.
ATA's long-standing partnership with CVS/pharmacy has raised more than $30 million through an ongoing annual fundraiser.
Our team has made great strides in the fight against ALS. Our ground-breaking research has been highlighted in many prestigious publications and journals, including GEN Generic Engineering & Biotechnology News, ScienceDaily, NeuroTalk, Drug Store News, Inscience Organisation and more.
Today, the ATA secures strategic partnerships with organizations who want to help fight this debilitating and deadly disease. Together with our partners, we're creating awareness of - and raising funds for - ALS research. We're seeking partnerships with biotech and pharmaceutical firms that want to be on the forefront of breakthrough research by partnering with a well-known, credible organization like the ATA.
Our Board of Directors consists of esteemed researchers, scientists and Nobel Laureates who are affiliated with top institutions, such as Massachusetts General Hospital, Harvard Medical School, Massachusetts Institute of Technology, Harvard College, Tufts University, Children's Hospital Boston, Brigham and Women's Hospital, Beth Israel Deaconess Hospital, Columbia University, Boston University, Brandeis University, and the University of Massachusetts Medical School.
In addition to the work in this country, the ATA is collaborating with scientists globally, working with scientists, researchers and physicians in Israel, China, Germany, India, Belgium, Mexico and Chile.
We invite you to learn more about us and discover how a partnership with the ALS Therapy Alliance will benefit your organization and help eradicate this horrible disease.
For more information and to discuss next steps, please contact Traci Bisson, Executive Director at email@example.com.